Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder

Expert Review of Neurotherapeutics

Volumn 2, Issue 5, 2002, Pages 717-724

  Baldwin, David ^a   Buis, Christel ^a   Mayers, Andrew ^a  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

Citalopram; Escitalopram; Fluoxetine; Fluvoxamine; GAD; Paroxetine; Sertraline; SSRI

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 4 AMINOBUTYRIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ABECARNIL; ALPRAZOLAM; AMITRIPTYLINE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DERAMCICLANE FUMARATE; DIAZEPAM DERIVATIVE; ESCITALOPRAM; FLESINOXAN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PREGABALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; VENLAFAXINE; YOHIMBINE;

AMNESIA; ANXIETY NEUROSIS; BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG EFFICACY; DRUG POTENCY; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOMOTOR DISORDER; PSYCHOTHERAPY; RELAXATION TRAINING; REVIEW;

EID: 0036046193     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.5.717     Document Type: Review

References (68)

1. Epidemiology of generalised anxiety disorder in the community and in primary care
2. One-year prevalence of subthreshold and threshold DSM-IV generalised anxiety disorder in a nationally representative sample
3. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey
4. Factors predicting the clinical course of generalised anxiety disorder
5. Anxiety disorders in later life: A report from the Longitudinal Aging Study Amsterdam
6. Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Healthcare
7. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys
8. The economic burden of anxiety disorders in the 1990s
9. The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases
10. Generalized anxiety disorder: Neurobiological and pharmacotherapeutic perspectives
11. Noradrenergic function in generalized anxiety disorder: Effects of yohimbine in healthy subjects and patients with generalized anxiety disorder
12. Noradrenergic function in generalized anxiety disorder, major depressive disorder and healthy subjects
13. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients
14. Peripheral-type benzodiazepine receptors in anxiety disorders
15. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study
16. A double-blind comparison of citalopram and paroxetine in the treatment of patients with depression and anxiety
17. Placebo-controlled comparison of the selective serotonin re-uptake inhibitors citalopram and sertraline
18. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer
19. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials
20. Escitalopram in the treatment of generalized anxiety disorder
21. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents
22. Fluoxetine: A review of its use in anxiety disorders and mixed anxiety and depression
23. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders
24. SSRIs in the treatment of generalised anxiety disorder
25. Paroxetine efficacy in the treatment of generalized anxiety disorder
26. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial
27. Continued benefit of long-term paroxetine treatment for generalised anxiety disorder
28. Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder
29. Improving the disability and impairment associated with generalised anxiety disorder with paroxetine treatment
30. Double-blind comparison of nefazodone, imipramine and placebo in major depression
31. An open trial of nefazodone in adult patients with generalised anxiety disorder
32. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed out-patients
33. Efficacy, safety and tolerability of venlafaxine extended release and buspirone in out-patients with generalised anxiety disorder
34. Efficacy of venlafaxine extended-release (XR) capsules in nondepressed out-patients with generalised anxiety disorder
35. Placebo-controlled evidence for the use of antidepressants in generalised anxiety disorder
36. Efficacy of short and long-term venlafaxine ER treatment for somatic and psychic symptoms of GAD
37. Efficacy of venlafaxine extended-release capsules in nondepressed out-patients with generalised anxiety disorder
38. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study
39. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: Results from a placebo-controlled trial
40. Meta-analysis of eight randomised, double-blind, controlled trials of mirtazapine, a novel antidepressant drug
41. Buspirone: A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic
42. The comparative efficacy of buspirone and diazepam in the treatment of anxiety
43. Use ofbuspirone in patients with generalised anxiety disorder and coexisting depressive symptoms: A meta-analysis of eight randomised controlled trials
44. Efficacy of buspirone in generalised anxiety disorder with coexisting mild depressive symptoms
45. Controlled comparison of buspirone and oxazepam in generalised anxiety
46. The spectrum of generalised anxiety in clinical practice: The role of short-term, intermittent treatment
47. Double-blind, placebo-controlled fixed dose study of flesinoxan in generalized anxiety disorder
48. Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: A preliminary meta-analysis
49. Limitations on the use of benzodiazepines in anxiety and insomnia: Are they justified?
50. The use of benzodiazepines in anxiety and other disorders
51. Abercarnil, a new beta-carboline, in the treatment of anxiety disorders
52. The first double-blind placebo-controlled trial of a partial BZD agonists abercamil (ZK-112-119) in generalised anxiety disorder
53. A double-blind evaluation of the safety and efficacy of abercamil, alprazolam and placebo in out-patients with generalised anxiety disorder
54. Abercarnil for the treatment of generalised anxiety disorder: A placebo-controlled comparison of two dose ranges of abercarnil and buspirone
55. Double-blind, placebo-controlled trial of two doses of abercarnil for geriatric anxiety
56. A double-blind, placebo-controlled study of a CCK-B antagonist, CIO-988, in patients with generalised anxiety disorder
57. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity
58. Pregabalin, a novel agent, in the treatment of generalized anxiety disorder
59. Comparison of the efficacy and safety of pregabalin and alprazolam in generalised anxiety disorder
60. Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: A preliminary meta-analysis
61. One year follow-up of cognitive therapy analytic psychotherapy and anxiety management training for generalised anxiety disorder: Symptom change, medication usage and attitudes to treatment
62. Interaction of pharmacological and psychological treatments of anxiety
63. Cognitive therapy versus behaviour therapy in the treatment of chronic generalised anxiety
64. Behaviour therapy and benzodiazepines: Allies or antagonists?
65. A controlled comparison of cognitive-behaviour therapy, diazepam and placebo, alone and in combination, for the treatment of generalised anxiety disorder
66. A comparison of nefazodone, the cognitive-behavioural analysis system of psychotherapy and their combination for the treatment of chronic depression
67. Cognitive-behavioural therapy, imipramine, or their combination for panic disorder: A randomized controlled trial
68. Guidelines for investigating efficacy in GAD